Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer.

Vaishampayan U, Shi D, Abdulfatah E, Aoun H, Wynberg J.

Urol Case Rep. 2019 Jan 28;23:103-105. doi: 10.1016/j.eucr.2019.01.018. eCollection 2019 Mar.

2.

Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.

Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM.

Cancer. 2017 Jul 1;123(13):2489-2496. doi: 10.1002/cncr.30620. Epub 2017 Mar 21.

3.

Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.

Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714-24.

PMID:
15708249
4.

The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.

Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

PMID:
26749093
5.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
6.

Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer.

Vuky J, Corman JM, Porter C, Olgac S, Auerbach E, Dahl K.

Oncologist. 2013 Jun;18(6):687-8. doi: 10.1634/theoncologist.2011-0234. Epub 2013 Jun 5.

7.

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A.

JAMA. 1998 Sep 16;280(11):969-74.

PMID:
9749478
8.

Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.

Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2016 Apr;69(4):728-733. doi: 10.1016/j.eururo.2015.10.009. Epub 2015 Oct 21.

PMID:
26497924
9.
10.
11.

Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.

Vuky J, Porter C, Isacson C, Vaughan M, Kozlowski P, Picozzi V, Corman J.

Cancer. 2009 Feb 15;115(4):784-91. doi: 10.1002/cncr.24092.

12.

Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study.

Nosov A, Reva S, Petrov S, Mamijev E, Novikov R, Veliev E, Imkamp F, Tolkach Y, Moiseenko V.

Prostate. 2016 Nov;76(15):1345-52. doi: 10.1002/pros.23165. Epub 2016 Feb 11.

PMID:
26864707
13.

Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.

Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV.

BJU Int. 2012 Oct;110(8):1116-21. doi: 10.1111/j.1464-410X.2012.11012.x. Epub 2012 Apr 30.

14.

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.

Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA.

Urology. 2001 Feb;57(2):281-5.

PMID:
11182337
15.

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.

McKay RR, Gray KP, Hayes JH, Bubley GJ, Rosenberg JE, Hussain A, Kantoff PW, Taplin ME.

Cancer. 2015 Aug 1;121(15):2603-11. doi: 10.1002/cncr.29398. Epub 2015 Apr 22.

16.

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.

Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA.

Urology. 2004 Jun;63(6):1138-42.

PMID:
15183967
17.

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK.

Cancer. 2012 Oct 1;118(19):4777-84. doi: 10.1002/cncr.27416. Epub 2012 Jan 26.

18.

Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.

Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P.

J Nucl Med. 2017 Dec;58(12):1972-1976. doi: 10.2967/jnumed.117.196683. Epub 2017 Jul 26.

19.

Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.

Grossfeld GD, Small EJ, Carroll PR.

Urology. 1998 Jan;51(1):137-44.

PMID:
9457309
20.

Supplemental Content

Support Center